ROKIT Healthcare: Q1 2026 Sales Up 118%, Massive 62.5B Won Fundraising and Subsidiary Nasdaq Listing

Consolidated revenue 8.06B KRW (up 118% YoY from 3.69B), operating loss 2.35B (vs profit 0.45B in prior year)
Raised approx. 62.5B KRW through equity and RCPS issuance (March 2026, 72% foreign capital)
Consolidated debt ratio surged to 936% (from 376% at end of 2025), derivative liabilities 46.6B KRW
Subsidiary ROKIT AMERICA filed for Nasdaq listing ($9.50/share, 2.63M shares, expected stake 90.48%)
Signed MOU with UAE royal family investment firm MIG for 30B KRW JV (April 2026)
Signed license agreement with Saudi LifeHope for CKD prediction AI algorithm (May 2026)
Consolidated net loss 1.88B (improved 32.8% from 2.80B loss in prior period)
Cash and equivalents 68.2B (from 31.1B), short-term financial instruments 10.7B, long-term 10.0B